

Number of shares and votes in Oncopeptides

STOCKHOLM — July 31, 2023 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company's issue of 219,843 new class C shares in accordance with the shareholder program Board SHP 2023 adopted by the annual general meeting on May 25, 2023.

Before the share issue, the total number of outstanding shares in Oncopeptides amounted to 94,309,267 and the total number of votes in Oncopeptides amounted to 90,762,720.7. As a result of the share issue, the number of outstanding shares in Oncopeptides has increased by 219,843 shares, corresponding to 21,984.3 votes. As of today, the total number of outstanding shares in Oncopeptides amounts to 94,529,110 shares, of which 90,368,660 are ordinary shares and 4,160,450 are class C shares. The number of votes in Oncopeptides as of today amounts to 90,784,705. The share capital has increased by SEK 24,427.000993 from SEK 10,478,807.870004 to SEK 10,503,234.870997.

For more information, please contact:

David Augustsson, Director of Corporate Affairs, Oncopeptides AB (publ)

E-mail: david.augustsson@oncopeptides.com

Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2023-07-31 08:00 CEST.

About Oncopeptides

Oncopeptides is a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases. The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells.

Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation. Melflufen has been granted accelerated approval in the US under the trade name Pepaxto®. The drug is currently not marketed in the US.

Oncopeptides is developing several new compounds based on its proprietary technology platforms and is listed on the Small Cap segment on Nasdaq Stockholm with the ticker ONCO. For more information see: www.oncopeptides.com.

Attachments

[Number of shares and votes in Oncopeptides](#)